二甲双胍抗肿瘤治疗的临床研究进展

Advances of clinical trials of metformin in antitumor therapy

二甲双胍不仅是最广泛使用的口服降糖药之一,还表现出降血糖作用外的多种疗效,如保护心脏作用、改善血脂作用及可能的抗癌作用。流行病学数据也显示服用二甲双胍的患者癌症发病率和死亡率均降低。随着研究的开展,二甲双胍作为一种潜在辅助抗癌药物引起了广泛关注。围绕二甲双胍作用机制及疗效的临床试验在不同癌种中陆续开展,随着更多临床试验的结果公布,二甲双胍与化疗、放疗、分子靶向药物或免疫治疗等联合治疗的效果以及对治疗前后某些代谢分子的表达影响均获得验证,为二甲双胍联合治疗癌症提供了更为明确的证据,有助于促进二甲双胍作为辅助抗癌剂的临床应用。

Metformin is one of the most widely used oral hypoglycemic drugs.Multiple studies have shown that metformin exhibits pleiotropic effects other than hypoglycemic effects,such as cardioprotective effects,improvements in the blood lipid profile,and possibly anticancer effects.Epidemiological data also show a reduction in cancer morbidity and mortality in patients treated with metformin.As research has progressed,metformin has attracted more attention as a potential and attractive adjuvant anticancer drug.Clinical trials on the mechanism and efficacy of metformin have been conducted in different cancers.With publication of the results of more clinical trials,the effects of metformin combined with chemotherapy,radiotherapy,molecular targeted drugs,or immunotherapy,and its effects on certain metabolic molecules will be verified.This could provide more definitive evidence of the benefits of metformin in combination with cancer therapy and facilitate the clinical application of metformin as an adjunctive anticancer agent.